510(k) device
OsteoSight Spine (v1)
Naitive Technologies, Ltd. · Radiology Software For Opportunistic Evaluation Of Low Bone Mineral Density (SAO, Class II) · First FDA decision Sep 2, 2025, newest Oct 27, 2026Osteoporosis and fragility fractures
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
0
Naming "OsteoSight"
MAUDE reports
0
Brand "OsteoSight", since 2015
PubMed studies
1
Mentioning "OsteoSight"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing OsteoSight Spine (v1)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- OsteoSight Spine (v1)510(k)
K261512 · Decided Oct 27, 2026 · 173 days after receipt
Device type: Radiology Software For Opportunistic Evaluation Of Low Bone Mineral Density (SAO) · Radiology & Imaging
- OsteoSight Hip (v1)Breakthrough510(k)
K251408 · Decided Sep 2, 2025 · 119 days after receipt
Device type: Radiology Software For Opportunistic Evaluation Of Low Bone Mineral Density (SAO) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Bone (Mineral) Density StudiesNational determinationOn the books150.3Updated Nov 4, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "OsteoSight", any status and sponsor, newest update first.
No registered device study names "OsteoSight".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "OsteoSight", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SAO
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "OsteoSight"[tiab]. The summary above synthesizes these.
- Opportunistic assessment of osteoporosis using hip and pelvic X-rays with OsteoSightࡊ: validation of an AI-based tool in a US population.
Pignolo RJ, Connell JJ, Briggs W, et al. · Osteoporos Int · 2025Validation Study
Other devices of this type
Also filed under product code SAO.
- DeepXray SpinaAlpha Intelligence Manifolds, Inc. · 510(k) 2026
- Rho16 Bit, Inc. · De Novo 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.